Hi WAG. I agree the shortened P3 is certainly a incentive to think about going it alone but it also means that for the next year we are solely focussed on Trofinetide P3 for Retts. A partnership deal would open up many more channels and alllow for further development and testing of 2591 which is exciting. Better path forward for the company and shareholders IMO.
2017...2018?, page-5
-
- There are more pages in this discussion • 246 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.22 |
Change
0.120(0.60%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.43 | $20.14 | $646.9K | 31.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.24 | 90 | 3 |
View Market Depth
| Last trade - 11.14am 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |